Back HCV Treatment

AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients

A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced, cirrhotic, genotype 1 hepatitis C patients without the need for ribavirin, according to study findings presented at the AASLD Liver Meeting this week in San Francisco.


Read more: